TY - JOUR
T1 - Results of surgical treatment after neoadjuvant chemotherapy for stage III non-small cell lung cancer
AU - Carretta, Angelo
AU - Ciriaco, Paola
AU - Melloni, Giulio
AU - Sayed, Imad
AU - Bandiera, Alessandro
AU - Ferla, Luca
AU - Puglisi, Armando
AU - Zannini, Piero
PY - 2008/12
Y1 - 2008/12
N2 - Background: The potential benefits of an approach combining neoadjuvant chemotherapy and surgery in stage IIIA and IIIB NSCLC have to be weighed against a potential increase in postoperative complications. We evaluated the results in terms of postoperative complications and survival in patients with stage III NSCLC who underwent complete surgical treatment after neoadjuvant chemotherapy with two regimens: mitomycin, vinblastine, and cisplatin (MPV) versus gemcitabine and cisplatin (GC). Methods: From March 1991 to September 2005, 110 patients with stage III NSCLC (86 stage IIIA and 24 stage IIIB) underwent complete surgical treatment after neoadjuvant chemotherapy. Ninety-two patients were men and 18 were women, with a mean age of 59 (range, 39-80) years. The neoadjuvant chemotherapy regimen was MPV in 72 patients and GC in 38. Results: The overall response (>50%) to chemotherapy was 84%. Postoperative mortality and morbidity were 1.8% and 20%, respectively. Overall 5-year survival was 46%. Minor response to neoadjuvant chemotherapy (
AB - Background: The potential benefits of an approach combining neoadjuvant chemotherapy and surgery in stage IIIA and IIIB NSCLC have to be weighed against a potential increase in postoperative complications. We evaluated the results in terms of postoperative complications and survival in patients with stage III NSCLC who underwent complete surgical treatment after neoadjuvant chemotherapy with two regimens: mitomycin, vinblastine, and cisplatin (MPV) versus gemcitabine and cisplatin (GC). Methods: From March 1991 to September 2005, 110 patients with stage III NSCLC (86 stage IIIA and 24 stage IIIB) underwent complete surgical treatment after neoadjuvant chemotherapy. Ninety-two patients were men and 18 were women, with a mean age of 59 (range, 39-80) years. The neoadjuvant chemotherapy regimen was MPV in 72 patients and GC in 38. Results: The overall response (>50%) to chemotherapy was 84%. Postoperative mortality and morbidity were 1.8% and 20%, respectively. Overall 5-year survival was 46%. Minor response to neoadjuvant chemotherapy (
UR - http://www.scopus.com/inward/record.url?scp=56349090842&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56349090842&partnerID=8YFLogxK
U2 - 10.1007/s00268-008-9774-7
DO - 10.1007/s00268-008-9774-7
M3 - Article
C2 - 18836761
AN - SCOPUS:56349090842
VL - 32
SP - 2636
EP - 2642
JO - World Journal of Surgery
JF - World Journal of Surgery
SN - 0364-2313
IS - 12
ER -